Quick Overview
- Shares of Novo Nordisk rallied over 6% following an FDA proposal to eliminate semaglutide, tirzepatide, and liraglutide from the 503B bulks compounding registry
- The regulatory agency maintains that outsourcing facilities have no clinical justification to compound these medications
- The public feedback window extends through June 29, 2026, preceding any final regulatory determination
- NVO reached its strongest position in more than 60 days, leading gainers on Copenhagen’s exchange Thursday
- Despite Thursday’s rally, shares remain down over 16% for the year
Shares of Novo Nordisk experienced a significant rally exceeding 6% on Thursday following the FDA’s announcement of proposed restrictions on weight-loss drug compounding, a regulatory shift that stands to directly advantage the Danish pharmaceutical giant.
The regulatory agency put forward a proposal to strike semaglutide, tirzepatide, and liraglutide from the 503B bulks registry. According to the FDA, outsourcing facilities lack clinical justification for compounding these particular medications.
The equity reached its strongest valuation in over 60 days during Thursday’s session and topped the list of gainers on Copenhagen’s primary exchange.
NVO was changing hands near $42.38 during the current session, significantly exceeding its 20-day moving average of $39.03 and surpassing its 50-day moving average of $38.87.
Despite the positive momentum from Thursday’s session, shares continue trading beneath the 200-day moving average of $50.32 and maintain a year-to-date decline exceeding 16%.
The regulatory body has initiated a public commentary window extending through June 29, 2026, prior to rendering any conclusive determination on the proposed policy.
Challenges Facing Novo Nordisk
Novo Nordisk has encountered several obstacles in recent months. Canadian health authorities granted approval for the initial generic alternative to Ozempic within Canada, introducing fresh competition in a significant market.
The pharmaceutical company responded by implementing a stock repurchase initiative. Since February 2026, the firm has acquired approximately 13.4 million B-shares valued at 3.44 billion Danish kroner, representing part of a 12-month, 15 billion kroner program.
Regarding developmental progress, the organization has initiated Phase 3 clinical testing for a knee osteoarthritis therapy and secured FDA fast-track status for a cardiovascular medication.
First quarter 2026 financial results are expected on May 6.
Technical Analysis Perspective
Near-term momentum indicators show positive signals. The MACD has generated a bullish signal while the RSI registers 54.73, indicating moderately favorable conditions.
Nevertheless, the ADX measurement of 17.26 indicates the trend demonstrates limited strength. The Stochastic RSI is generating a bearish signal, suggesting potentially overextended conditions.
Anton Kharitonov from Traders Union highlighted the delicate technical position, noting that subdued momentum readings and overextended levels indicate purchasing pressure may diminish rapidly. He identified the generic Ozempic threat in Canada as an additional headwind.
Viktoras Karapetjanc, representing Traders Union, maintains a more optimistic outlook. He views the repurchase initiative and robust clinical development pipeline as fundamental supports, characterizing the recent decline as a possible springboard.
Market analyst Jainam Mehta identifies a critical trading zone between $40.78 and $43.23 as the significant area to monitor. He emphasized that a definitive move beyond either threshold would be necessary to alter the immediate-term risk assessment.
Shares commenced Thursday’s session with an upward gap of approximately $0.37 and advanced $1.94, representing 4.80%, during intraday trading. Intraday price fluctuation measured 2.47%.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
